Author

Tirsa L.E. van Westering

Charles River Laboratories (Netherlands)ORCID 0000-0003-0278-1245Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

Anna M. L. Coenen-StassiD· 1 shared Junyu Huang· 1 shared Kaarel KrjutškoviD· 1 shared Matthew J. A. WoodiD· 1 shared Samir EL AndaloussiiD· 1 shared Sofia StenleriD· 1 shared Thomas C. RobertsiD· 1 shared Yahya E. JadiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Anna M. L. Coenen-StassORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

NeuroscienceMolecular Therapy — Nucleic AcidsPeer-reviewedJul 17, 2026

Timing matters: exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy

Sofia Stenler, Junyu Huang, Tirsa L.E. van Westering…·Thomas C. Roberts

This study shows that exon skipping therapy is more effective when started early in adult mdx mice than in aged mice, leading to better dystrophin restoration and transcriptomic changes.

DOI 10.1016/j.omtn.2026.103017

mousebulk RNA-seq

𝕏 PostBluesky